WealthStone’s Alnylam Pharmaceuticals ALNY Stock Holding History

WealthStone’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-7	Closed	-$507	–	72
2019 Q2	$507	Buy	+7	New	+$537	﹤0.01%	884

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

WealthStone's ALNY Position: Q3 2019 in Review

WealthStone sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2019, closing a stake of 7 shares — an estimated $507 sold.

WealthStone first reported a position in ALNY in Q2 2019 and held it in 1 quarter. The position peaked at $507 in Q2 2019. 281 funds tracked by Wall St. Rank hold ALNY as of Q3 2019.

WealthStone reported no remaining Alnylam Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
WealthStone sold 7 Alnylam Pharmaceuticals shares in Q3 2019, an estimated $507.
WealthStone first reported a position in Alnylam Pharmaceuticals in Q2 2019 and held it in 1 quarter.
WealthStone's Alnylam Pharmaceuticals position peaked at $507 in Q2 2019.
281 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2019.

Based on WealthStone's 13F filing for Q3 2019, filed 15 Nov 2019.